Corvia Medical closes $55 million funding round to complete confirmatory trial and pursue FDA approval of Corvia Atrial Shunt | Corvia Medical

▤ Summary

Corvia Medical closed a $55 million funding round led by its existing investors and two strategic investors. The company will use the capital to complete the RESPONDER-HF confirmatory trial for its Corvia Atrial Shunt. The trial is designed to generate the final clinical data needed for FDA approval in heart failure patients with preserved or mildly reduced ejection fraction. Corvia Medical says the financing will help it move through the approval process and bring the device to market.

$ Funding

▦ Linked Companies